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A B S T R A C T
The number of elderly people has increased considerably over the last decades, due to a rising life expectancy
and ageing populations. As a result, an increased number of elderly with end-stage-renal-disease are diagnosed,
for which the preferred treatment is renal transplantation. Over the past years the awareness of the elderly as a
speciﬁc patient population has grown, which increases the importance of research in this group.
Elderly patients often receive kidneys from elderly donors while younger donor kidneys are preferentially
reserved for younger recipients. Although the rate of acute rejection after transplantation is lower in the elderly,
these rejections may lead to graft loss more frequently, as kidneys from elderly donors have marginal reserve
capacity. To prevent acute rejection, immunosuppressive therapy is needed. On the other hand, elderly patients
have a higher risk to die from infectious complications, and thus less immunosuppression would be preferable.
Immunosuppressive treatment in the elderly is complicated further by changes in the pharmacokinetics and
pharmacodynamics, with increasing age. Adjustments in standard immunosuppressive regimes are therefore
suggested for this population.
An unmet need in transplantation medicine is a tool to guide a personalized approach to immunosuppression.
Recently several promising biomarkers that identify injury to the graft at an early stage or predict acute rejection
have been identiﬁed. Unfortunately, none of these biomarkers were tested speciﬁcally in the elderly. We believe
there is an urgent need to perform clinical trials investigating novel immunosuppressive regimens in conjunction
with biomarker studies in this speciﬁc population.
1. Introduction
Over the past decades the number of elderly people (in this manu-
script deﬁned as patients older than 65 years) has increased sub-
stantially and is expected to rise even further from 8% of the total world
population in 2015 to 16% in the year 2050 [1–3]. This increase does
not only aﬀect health care in general, but also has a great impact on
more speciﬁc issues, such as the increased number of patients with end-
stage-renal-disease (ESRD) [1,2,4–6]. In younger patients (< 65 years),
renal transplantation (RT) has been the preferred treatment option for
ESRD for many years. The beneﬁts of RT, however, have been less es-
tablished for elderly patients. This, together with the poor availability
of donor kidneys, is a reason why there has been reluctance to put the
elderly on the waiting list for RT [7].
Over the past few years, research has focused more on the treatment
of ESRD in the elderly. The results of these studies indicate that RT in
elderly patients is also associated with reduced mortality compared to
dialysis [8,9] We now see a gradual increase in the proportion of elderly
patients in the total population of transplanted patients [10]. Not
surprisingly, transplantation of the elderly recipient is more compli-
cated because of pre-existing comorbidities, frailty, changes in phar-
macokinetics (PK) of (immunosuppressive) drugs, polypharmacy and
changes in immunoreactivity (immunosenescence). In this paper, we
will brieﬂy review these topics and provide recommendations on how
to increase the chances of success of RT in the elderly.
2. Beneﬁts of transplantation in the elderly
Although RT is beneﬁcial in elderly patients with a reduction in
mortality rate and an improved quality of life compared to dialysis
[1,8,9,11], mortality and quality of life only improve with a functioning
graft. This applies to every transplant and recipient without taking age
into account. It is therefore important to maintain allograft function.
The 10-year renal allograft survival rate of deceased donor kidneys is
close to 50%, and poorer long-term outcome is associated with several
variables [12]. One of the risk factors for poor long-term outcome is
acute rejection [13,14] Data from the United States indicate that
transplantation from living donors to elderly recipients increased until
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2010 and remained stable in the last couple of years, while transplan-
tation from living donors to younger recipients decreased [10]. In
Europe multiple organizations are involved in the allocation and ex-
change of deceased donor organs. There are big diﬀerences between
European countries in the proportions of living and deceased donor
kidney transplantation. For example, in the Netherlands the majority of
patients (58%) are transplanted with a kidney from a living donor, but
in countries where more deceased donor kidneys are available, such as
in Belgium or Austria, living donation is a much smaller part of the
transplant program (13% and 15%, respectively) [15].
2.1. Eurotransplant senior program
Elderly patients often receive kidneys from elderly donors, because
kidneys of younger donors are mostly allocated to younger recipients.
The Eurotransplant Senior Program (ESP) is a specially designed pro-
gram that was set in place to solve the kidney shortage in the elderly. In
this program, kidneys from older donors are preferentially allocated to
elderly recipients without matching for HLA antigens and over a narrow
geographic area [1,4] Because this process is less comprehensive than
standard allocation, cold ischemia time is minimized whereby the
chance of delayed graft function (DGF) and rejection are reduced [16].
The results of this program were evaluated by Peters-Sengers et al.
who made a distinction in donors after brain death (DBD) or after cir-
culatory death (DCD) [17]. They found less acute rejection in the el-
derly after receiving kidneys from young DBD and DCD donors
(< 65 years) compared to younger recipients receiving kidneys from
these same donors. Similar results were found in elderly patients who
received kidneys from elderly DBD donors. The incidence of acute re-
jection was 13.5% in the elderly population compared to 17.9% in the
group of younger recipients. This is most likely due to im-
munosenescence which will be explained later on. However, more acute
rejection was seen in elderly recipients after receiving kidneys from
elderly DCD donors. This is probably the result of more ischemia-re-
perfusion injury due to the longer warm ischemia time of older DCD
kidneys [17].
Also research has shown that elderly patients with ESRD beneﬁt
from RT, even when kidneys from older donors are used [18]. Their
immune system is less reactive and therefore they are less prone to
acute allograft rejection and graft loss [19]. However, acute rejection in
elderly recipients is still a major problem because it is associated with a
dramatic decrease in long-term graft survival, especially when elderly
patients have received a kidney from a marginal donor. A potential way
to intervene is to apply the principles of personalized medicine (see
below).
3. Pharmacokinetics and pharmacodynamics
After RT, combinations of immunosuppressants are prescribed to
prevent renal allograft rejection. Worldwide, combined treatment with
tacrolimus, mycophenolic acid (MPA), glucocorticoids and basiliximab
induction therapy is most frequently used [19–21]. During ageing,
signiﬁcant changes in both the PK and pharmacodynamics (PD) of
immunosuppressive drugs may result in diﬀerent outcomes of trans-
plantation.
3.1. Pharmacokinetics
Staatz et al. summarized all available published data on the PK of
tacrolimus in a review and concluded that a lower dose of tacrolimus in
elderly patients could still be eﬀective and was possibly safer than the
standard dose [22]. Over the last years several studies have conﬁrmed
this hypothesis with clinical trials (Table 1) [23]. The best evidence
comes from the study by Jacobson et al. They found that older re-
cipients had higher dose-normalized tacrolimus concentrations than
young adults [24]. Comparable results were found for ciclosporin.
Despite receiving lower doses of ciclosporin and tacrolimus, elderly
recipients often had higher predose concentrations of CNIs compared to
younger recipients [24]. These ﬁndings indicate that adjustment of the
starting doses of tacrolimus and ciclosporin in the elderly after RT is
needed in order to avoid over-exposure.
However, these changes in PK of tacrolimus are not representative
for all immunosuppressants. Tang et al. demonstrated that the PK of
MPA is not aﬀected by the physiological changes in the elderly. In this
study, oral MPA was given to younger (43.7 ± 4.9 years) and elderly
(65.8 ± 4.9 years) renal transplant recipients [25]. No signiﬁcant dif-
ference was found in the PK of MPA [25]. Also elderly patients do not
need dose adjustments for basiliximab as the PK does not change with
age [26].
Drug plasma/whole blood concentrations are aﬀected by ADME
(absorption, distribution, metabolism and elimination) of the drug.
Most immunosuppressants are administered orally, and changes in
gastrointestinal (GI) absorption are the ﬁrst factor that may alter blood
concentrations [27]. Oral absorption of medication by passive diﬀusion
can be reduced by a decrease in gastrointestinal motility, reduced
splanchnic blood ﬂow, reduced gastric acid secretion and the dimin-
ished intestinal surface area [19,28,29] These changes may occur with
increasing age. The eﬀects of ageing on p-glycoprotein (p-gp) expres-
sion are largely unknown and no correlation could be found between p-
gp expression in intestinal tissue and patient age (21–67 years).[22,30]
Distribution of a drug is highly dependent on the lipophilic or hydro-
philic character of a speciﬁc drug. With increasing age the body com-
position gradually changes, with a decline in muscle mass and an in-
crease in body fat [28,29,31]. Although some studies indicate that due
to this change in body composition the volume of distribution (Vd) of
lipophilic drugs increases, a study of Jain et al. found that the Vd, ad-
justed for total body weight, in obese patients could not be predicted
based on lipophilicity alone [32]. The Vd of ciclosporin for example was
decreased in obese patients which is in contradiction with its lipophilic
character. It was suggested that this was due to binding to lipoprotein
or additional tissue distribution [32]. Increased body fat was also as-
sociated with a prolonged elimination half-life of tacrolimus and ci-
closporin in patients with a mean age of 44 years [33–35]. Given the
fact that elderly patients also have a higher amount of body fat, these
results are likely to also apply to this group of patients. During a pa-
tient’s lifetime drug-metabolizing capacity changes [28]. There is a
reduction in liver volume and liver blood ﬂow which is thought to be
the main cause of changes in drug metabolism during ageing [36].
Moreover, phase I metabolism and activity of Cytochrome P450 (CYP)
enzymes are both diminished by ageing [18,37].
In general, renal function deteriorates with age, and for drugs that
are renally excreted doses need to be reduced in elderly patients [33].
Passey et al. identiﬁed age as a signiﬁcant covariate towards tacrolimus
clearance in a population pharmacokinetic model [38]. The role of the
kidney in the excretion of the currently used immunosuppressive drugs
is very limited, and a reduced renal function in elderly patients is un-
likely to aﬀect the PK of these drugs.
3.2. Pharmacodynamics
PD describe the eﬃcacy and toxicity of drugs. For some im-
munosuppressants direct biomarkers are available that reﬂect their PD.
Tang et al. measured 5’monophosphate dehydrogenase (IMPDH) ac-
tivity in MPA treated elderly (± 65.8 years) and younger
(± 43.7 years) recipients after RT [25]. As no changes between the two
groups were found in IMPDH activity, the authors concluded that age
does not aﬀect the PD of MPA [25]. PD of CNIs can be measured by
means of the calcineurin activity, which is associated with acute re-
jection [39]. However, no studies were carried out to link calcineurin
activity to ageing.
The PD of immunosuppressive drugs may be inﬂuenced by co-
morbidities. Wu et al. used the Charlson Comorbidity Index (CCI) to
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deﬁne comorbidities in RT patients [40]. Patients who were included in
the high comorbidity group (CCI score> 5) had a crude hazard ratio of
1.42 [95%-CI 1.02–1.97] for kidney survival compared to patients with
a low CCI score. Furthermore, crude hazard ratio for patient survival
during a period of 80 months was 2.88 [95%-CI 1.90–4.37] between the
low- and high CCI index patients. This implies that not only graft sur-
vival is diminished but comorbidities are also a risk for overall survival
[40]. Elderly patients generally have more comorbidities such as dia-
betes and heart failure [41,42]. This does not mean that the presence of
comorbidities should preclude the patient from having access to
transplantation. In patients with chronic heart failure and RT, symp-
toms of heart failure even improved after receiving a donor kidney
[43]. No studies were carried out to determine graft survival in this
population, which is possibly due to the beneﬁts of RT on the co-
morbidity itself [37].
The classic immunosuppressive drugs have been selected based on
inhibition of T-cell activation [19]. During ageing, a shift takes place
towards the diﬀerentiation of memory cells, especially TEM cells [44].
As a result the antigen-recognition repertoire is decreased and the im-
mune system is therefore unable to protect the host properly against
new pathogens [45]. This was observed in several studies which de-
monstrated that elderly patients had an increased susceptibility to in-
fectious disease and cancer, but also a reduced response to vaccination
[33,46–48]. Furthermore, a decline in T-cells during ageing was mea-
sured due to the loss of thymic tissue which is responsible for ma-
turation of native T-cells [49,50]. This decline was also seen by De-
necke et al. who investigated the activation of CD4+ T-cells in old
recipient mice. [51]. They found an increase of early activated T-cells
and memory T-cells, but this was not related to intracellular cytokine
production. These ﬁndings were conﬁrmed in humans as less acute
rejection was seen in older recipients (> 50 years) compared to
younger recipients (< 50 years). Older donor kidneys are more im-
munogenic, but the resulting higher incidence of acute rejection seen in
younger recipients is less evident in the elderly recipient [52,53]. Be-
cause of the age-related changes in T-cell diﬀerentiation, the PD of
immunosuppressants is also changed and one of the reasons why the
dose of these drugs can be reduced (see Table 1).
Also, co-medication can lead to PD interactions in terms of adverse
eﬀects. It is well known that CNI’s can cause acute and chronic ne-
phrotoxicity [54]. A recent study from Khan et al. focused speciﬁcally
on acute kidney injury in the elderly patient and the cumulative or
synergistic nephrotoxicity of CNIs with nonsteroidal anti-inﬂammatory
drugs (NSAIDs), aminoglycosides, angiotensin-converting enzyme in-
hibitors (ACEi) and antimicrobial medication [55–58]. Because elderly
patients are more prone to acute kidney injury after transplantation, it
is necessary to minimize the use of nephrotoxic co-medication [55].
4. Frailty
Another factor that is associated with poor outcome after RT is
frailty. Recently frailty was deﬁned as a combination of diminished
strength, reduced physiologic function and increased vulnerability to
stressors [59,60]. Frailty is hard to diagnose because symptoms overlap
with the overall decline of physiological systems in the elderly. [59].
Frailty was found to be an independent risk factor for mortality and it
was associated with a poor outcome after RT [61,62]. This was also due
to the surgical transplant procedure. Frailty scores pointed out that
19.8% of a population with an average age of 53 years was frail before
RT. One month after surgery this increased to 33.3% and gradually
declined over the months following transplantation to 17.2% [62].
Preoperative frailty was associated with a 1.94-fold increased risk of
DGF [63]. This phenomenon was not related to the recipient’s age,
indicating that younger recipients diagnosed with frailty are at risk too.
Because the elderly have several other risk factors that are of inﬂuence
on graft failure, it is important to identify frailty at an early stage.
Hereafter a more balanced decision can be made regarding RT.
5. Optimization of therapy
Based on the fact that the elderly patient has a reduced immune
response to the transplanted organ, it may be possible to reduce the
overall immunosuppressive load. As prospective randomized trials
comparing diﬀerent regimens in elderly patients have not been per-
formed, one can only speculate on which drug should be reduced or
stopped. One could propose to leave out basiliximab induction therapy
in elderly patients, as the beneﬁts of induction therapy may be less
because they have a reduced IL-2 response [34]. Furthermore, in el-
derly patients, one may encounter severe infectious complications for
which a rapid reduction of the immunosuppressive load might be
needed. Obviously, the eﬀects of basiliximab, with its long elimination
half-life of approximately one week, are long lasting [64]. Another
option would be to taper glucocorticoids more rapidly in elderly pa-
tients. There is an ongoing debate regarding the safety of glucocorticoid
avoidance or tapering strategies. In elderly patients the balance be-
tween risks and beneﬁts of glucocorticoid minimization may be dif-
ferent compared to younger patients, also in view of their higher risk of
developing diabetes, cardiovascular disease and osteoporosis after
transplantation [65–67]. There is only little evidence that tapering or
withdrawal of glucocorticoids after RT in elderlies is beneﬁcial, but
long-term survival could be prolonged if comorbidities are prevented
[68].
Recent research suggested that everolimus-based therapy has the
potential to improve outcome after transplantation as it allows for CNI-
free or minimized CNI-based treatment [69,70]. A major advantage of
using everolimus in elderly patients would be the avoidance of the
Table 1
Overview of published data on pharmacokinetic parameters of tacrolimus in elderly people (≥65 years).
Author Year Age of patients Main ﬁndings
David-Neto et al. [23] 2016 Elderly: ≥65 years • Mean TAC dose was lower in elderly (8.6 mg ± 4.8 vs 12.1 ± 5.1mg).• Mean trough levels (Cmin) were the same in both groups• Elderly vs control: Adj Cmax [465 ± 271 vs 341 ± 235] (Adj for dose/body weight)• Elderly vs control: Adj TAC-AUC [2652 ± 1730 vs 2793 ± 1253] (Adj for dose/body weight)• Body clearance was lower in elderly [0.35 ± 0.31 vs 0.76 ± 0.42]
Control: 35 ± 6 years
Melilli et al. [75] 2015 Elderly: ≥65 years (35%) • TAC level at 5–7 days was lower in elderly vs patients< 65 years (8.05 ng/ml vs 7.1 ng/ml)• At 1, 3 and 6 months the levels between the groups were equal.non-elderly: < 65 years
Robertsen et al. [76] 2015 Elderly: 60–78 years Diﬀerences between original and generic TAC formulations:
• AUC0-12 of the generic formulation was 1.17 [90%-CI 1.10–1.23]• Cmax ratio 1.49 [90%-CI 1.35–1.65]
Jacobson et al. [24] 2012 Elderly: 65–84 years • Elderly had a higher normalized TAC trough with a lower median dose (1–2mg/day lower) compared to middle
and young ageMiddle age: 35–64 years
Young: 18–34 years
TAC= tacrolimus, Adj= adjusted, CI= conﬁdence interval, AUC=Area Under Curve.
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nephrotoxic eﬀects associated with tacrolimus treatment. Elderly pa-
tients often receive ECD kidneys from elderly donors, and as a result,
renal function after transplantation is often disappointing. In order to
reduce the proportion of patients with an eGFR below 30mL/min per
1.73m2, an everolimus-based immunosuppressive regimen may be
beneﬁcial. Also, because IL-2 production is decreased in the elderly,
tacrolimus could be less eﬀective [71]. In patients with lower IL-2
concentrations, it may therefore be attractive to replace tacrolimus by
everolimus. In a recent study of David-Neto et al. everolimus was given
to elderly patients in combination with tacrolimus and prednisone [72].
No diﬀerences were seen in the PK of everolimus during the ﬁrst 6
months after transplantation compared with younger recipients. How-
ever, the sample size was small (n= 16) and the association between
the use of everolimus and acute rejection was not investigated.
6. Potential biomarkers
For the management of transplanted patients, and to reach true
individualized therapy, biomarkers would be very helpful. Instead of
dosing immunosuppressive drugs based on a pharmacokinetic mea-
surement, an immunological biomarker would better reﬂect the activity
of the drug (or drug combination), rather than its mere concentration.
In a recent and comprehensive review of the use of biomarkers in
transplantation by Brunet et al., three types of biomarkers are dis-
cussed: [1] those associated with the risk of rejection (alloreactivity/
tolerance), [2] those reﬂecting individual response to im-
munosuppressants, and [3] those associated with graft dysfunction.
Brunet et al. conclude that it is likely that in transplanted patients, in
whom many factors inﬂuence the outcome, multiple predictive bio-
markers will need to be integrated with parameters such as time after
transplantation, previous rejections and infectious complications. In-
creased use of integrated PK-PD modeling will allow for balanced de-
cision making [73].
No speciﬁc biomarkers have been identiﬁed for elderly patients.
Since elderly patients appear to be especially vulnerable to the toxicity
of immunosuppressive therapy, such biomarkers are of special im-
portance in this population [55,73].
7. Conclusions
Two decades ago, Meier-Kriesche et al. pointed out that trans-
planted elderly patients are at risk for death due to severe infectious
complications, while they are less likely to reject their kidneys.
Although this observation advocates for a tailored immunosuppressive
regimen for this growing patient population, in daily practice elderly
patients are still treated with the same immunosuppressive regimens
and with the same doses and maintained at the same target con-
centrations as non-elderly patients [74]. Another factor to consider is
the preferential allocation of kidneys from elderly donors to elderly
recipients. These ECD-kidneys are more sensitive to the nephrotoxic
eﬀects of CNIs, and thus a CNI-free or low-CNI exposure im-
munosuppressive regimen could be of beneﬁt for these patients.
Besides a modiﬁed immunosuppressive regimen there is also an
unmet need to develop biomarkers that reﬂect the PD eﬀect of the
immunosuppressive drugs. A so-called “immunometer” would be able
to identify patients that are either under- or over-immunosuppressed,
and in these patients the dose of the immunosuppressive medication
could then be adapted to prevent rejection or manifestations of over-
immunosuppression. Ideally such a test should reﬂect the overall state
of immunosuppression, taking into account both the physiological re-
duced immune reactivity of the elderly patient, the alloreactivity to-
wards the allograft, and the biological eﬀect of the immunosuppressive
drug combination.
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